胺在状态:现在有多快?
1Department of Neurology, Lamezia Terme Hospital, 88046 Catanzaro, Italy.
Neurology international
|June 25, 2025
概括
状态 (SE) 是一种神经紧急情况. 早期服用胺,特别是在Stage 1 Plus SE,可以改善发作控制,并可以防止输管,提供比米达佐拉姆更好的安全性.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 状态 (SE) 是一种神经紧急情况,通常对初始的类 (BDZ) 治疗有抗性.
- 阶段1Plus在治疗前确定可能的BDZ抗性SE病例,其特点是长时间的发作,最小的运动症状和急性中枢神经系统病因.
- 长期SE中的GABA受体内化可能会导致BDZ耐药性,这表明了其他治疗点.
研究的目的:
- 审查关于在SE早期使用胺含聚疗法的证据.
- 总结目前关于胺在早期,成熟和耐火性SE的疗效的证据.
- 评估胺在管理BDZ耐药性SE中的作用,包括Stage 1 Plus.
主要方法:
- 对9项研究进行了系统审查.
- 分析胺在组合疗法和作为主要药物在各种SE阶段的使用情况.
- 评估控制,安全性概况和与胺剂的管理相关的临床结果.
主要成果:
- 结合米达佐拉姆 (Midazolam) 的胺基囊在儿科发作1+SE阶段的治疗中显示出有效性.
- 早些时候 (在发病12小时内) 服用胺可显著改善耐火性SE的控制.
- 氨酸在耐火性SE中表现出比米达佐拉姆更有利的安全性,并可能防止输管.
结论:
- 在早期的SE管理中,应考虑使用胺,特别是在1阶段以上的病例中,可能与一线BDZ一起使用.
- 胺是一种可行的第一线麻醉剂,用于耐火性SE,特别是在从Stage 1 Plus进展时.
- 有效的SE终止需要胺剂量超过0.9毫克/千克/小时,潜在的好处包括减少ICU停留时间.
关键词:
胺基氨酸 (ketamine) 是一种可以这是一种NMDA抗体.第1阶段加1阶段在状态的急性病因.作为一种类药物,它是 benzodiazepine.抗二胺药物耐药性状态 性发作综合多疗法综合多疗法长时间的状态性状态 性 的状态更多相关视频
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
17.9K
06:58Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
19.4K
相关概念视频
Parenteral Anesthetics: Overview
211
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
211
Cardiopulmonary Resuscitation IV: Pharmacological Management
84
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
84
Depolarizing Blockers: Pharmocokinetics
389
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
389
Depolarizing Blockers: Mechanism of Action
1.9K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.9K
Electroconvulsive Therapy
205
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
205
Antiepileptic Drugs: Potassium Channel Activators
289
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
289
